Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Q3 2022 Earnings Presentation
16 slides from Laboratorio Reig Jofre's earnings presentation, 2022
Slide 1: 3Q Results Third Quarter of 2022
3Q RESULTS Third Quarter of 2022
Slide 2: Table of Contents
TABLE OF CONTENTS 01 2022 Q3 RESULTS 02 INCOME STATEMENT AND BALANCE SHEET 03 2022 OUTLOOK 04 RJF SHARE PERFORMANCE
Slide 3: Q3 2022 Results
RESULTS O01 fet REIGIQJOFRE ~=
Slide 4: Results from Third Quarter of 2022
RESULTS FROM THIRD QUARTER OF 2022 REIG JOFRE had 13% growth in revenue and 6% growth in EBITDA at the end of September 2022 The cumulative sales figure in the third quarter of 2022 reached €195 million, exceeding the same SALES + 13% period in 2021 by 13%. The growth in pharmaceutical technology
Slide 5: Revenues by Business Unit
REVENUES BY BUSINESS UNIT PHARMACEUTICAL SPECIALITY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC Energy Injectables/Lyophilisates Dermatology Stress and sleep Weight management 87,6 51,1 Beauty 56,6 45 % million € 29 % million € 26 % million € +15% +5% +19 % The Consu
Slide 6: Sales by Geographical Area
SALES BY GEOGRAPHICAL AREA Rest of Rest of SPAIN EUROPE WORLD 45% 45% 10% €87.2 €88.8 €19.2 million million million Spain European 45% + 17% - 2% Union + 13% 39% The Spanish market shows acceleration compared to the first quarter, in which it grew by 6%. The increased consumption of antibiotics, t
Slide 7: Income Statement and Balance Sheet
INCOME STATEMENT AND BALANCE SHEET 02
Slide 8: Income Statement
INCOME STATEMENT 2022/2021 Outlook Q3 2022 miles euros 30/09/2022 30/09/2021 We highlight a 13% growth in sales figures, with a gross margin of Importe neto de la cifra de negocios 195.257 173.174 59%, slightly below the previous year due to the increasing pressure on the cost of materials and the
Slide 9: Balance Sheet and 2022 Investment
BALANCE SHEET 8.0 Q3 2022 miles euros 30/09/2022 30/09/2021 2022 INVESTMENT ACTIVO million euros Fondo de comercio 29.485 29.891 Otros activos intangibles 73.196 79.794 Inmovilizado material 91.549 92.885 R&D Inversiones contab. método Participación 2.216 1.911 CAPITALISATION CAPEX Instrumentos de p
Slide 10: Balance Sheet: Net Financial Debt
BALANCE SHEET Q3 2022 NET FINANCIAL DEBT Debt|EBITDA miles euros 30/09/2022 30/09/2021 64.1 TOTAL PATRIMONIO NETO 191.107 189.134 close of close of Q322 million euros Q322 2.2 Subvenciones 3.916 2.349 Provisiones 201 287 2021 69.0 2021 Pasivos financieros entidades de crédito 28.565 32.972 year- mil
Slide 11: Outlook
OUTLOOK 2022 SS fet REIGIQJOFRE ~=
Slide 12: Outlook 2022
2022 At the end of September REIG JOFRE confirmed the revenue and profits growth trend of the first quarters of 2022 and expects to end the year well with double-digit growth in sales and an acceleration in the Outlook growth of earnings. In a market context in which demand for hospital products is
Slide 13: RJF Share Performance
RJF SHARE PERFORMANCE ey REIGQIJOFRE ~=
Slide 14: RJF Share Performance 2022
RJF SHARE PERFORMANCE 2022 MARKET CAPITALISATION €178 million Data as at 30 September 2022 SCRIP DIVIDEND 2022 5,00 • Remuneration €0.04/right cash or shares Close • 97.2% of shareholders opt for shares 4,50 31/12/21 • 990,533 shares issued (1.26% capital) 4,00 3,26€ 3,50 AVERAGE DAILY VOLUME 3,00 •
Slide 15: Links and Extra Information
LINKS AND EXTRA INFORMATION LATEST NEWS RESULTS WEBCAST SUBSCRIPTION CENTRE www.reigjofre.com/en/news/ www.reigjofre.com/en/investors/webcasts/ www.reigjofre.com/en/news/subscription-center/
Slide 16: Thank you
3Q Thank you Av. de les Flors 08970 Sant Joan Despí, Barcelona, Spain Tel. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com